Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT07862933
Recruiting Not applicable

AI-Based Conversational Social Support for Older Adults With Heart Failure

NCT07862933 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Chang Gung University of Science and Technology
Phase
Not applicable
Started
2025-11-05
Last updated
2026-10-16

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

AI-Based Conversational Social SupportCommunity Social Participation

AI-Based Conversational Social Support: Participants will receive an AI-based conversational social-support intervention delivered via a tablet. The intervention is designed to provide social interaction and support for older adults with heart failure.

Community Social Participation: Participants will be encouraged to attend regular community social activities to enhance social interaction, with continued care and follow-up by telephone.

Study summary

This three-year study aims to investigate gender differences in social frailty and evaluate the effects of an artificial intelligence (AI)-based conversational social-support intervention among older adults with chronic heart failure (CHF).

The study plans to enroll 300-500 adults aged 60 years or older from four Chang Gung Memorial Hospital branches in Taiwan.

In the first phase, researchers will assess participants' clinical characteristics, sarcopenia, physical activity, and physical, psychological, and social frailty. The study will examine gender differences and identify factors associated with social frailty.

In the second phase, 174 participants are planned to be assigned to three groups: an AI-based conversational social-support group, a community social participation group, and a control group. The AI group will engage in daily 15-30-minute app-based conversations, while the community group will be encouraged to participate in regular social activities. The control group will maintain routine activities.

The third phase will assess longer-term changes in social frailty, emotional well-being, physical activity, and health outcomes, with follow-up assessments at 1, 3, 6, and 12 months after the intervention.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Participants aged 60 years or older. 2. Diagnosis of chronic heart failure (CHF). 3. Ability to communicate effectively in Mandarin or Taiwanese. Exclusion Criteria: 1. Unstable heart failure. 2. Severe comorbidities, such as end-stage renal disease, advanced hepatic dysfunction, or terminal malignancies. 3. Severe cognitive deficits that impede the ability to provide informed consent or participate in study interventions. 4. Uncorrected visual or hearing impairments that hinder effective communication or interaction with the AI-based conversational social-support intervention. 5. Active psychiatric conditions, including major depression or psychosis, that could interfere with study participation or adherence.

Primary outcome measure(s)

  • Change in Social Frailty Score — Baseline and 1, 3, 6, and 12 months after intervention
    Change in social frailty will be assessed using the five-item Makizako Social Frailty Index. Each item is scored as 0 or 1, yielding a total score ranging from 0 to 5. Higher scores indicate greater social frailty and therefore worse outcomes. Changes in scores will be compared among the AI-based conversational social-support intervention group, community social participation group, and control group.

Trial sites (2)

FacilityCityRegionStatus
New Taipei Municipal Tucheng Hospital (Built and Operated by Chang Gung Medical Foundation) New Taipei City New Taipei City Recruiting
Chang Gung Memorial Hospital, Linkou Taoyuan Taoyuan City Recruiting

More Chang Gung University of Science and Technology trials in Taiwan

Effects of Multi-strategy Evidence-based Education Training Programs on Knowledge, Attitude, and Preventive Behavior Towards Surgical Smoke Hazards Among Operating Room Nurses Recruiting
Effectiveness of a Tele-cardiac Rehabilitation (Tele-CR) Program Enrolling by invitation
Effects of AI Dialogue-Based Scenario Simulation on Students' Flow and Learning Performance Starting soon
The Impacts of Mindfulness on Psychological Wellbeing Among Nursing Students Recruiting
Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity Recruiting

Other trials for the same condition

Home-based Cardiac Rehabilitation With Spot-jogging Active, not recruiting
Effects of a Wed-based FRAIL-SM Program Among Patients With Heart Failure Starting soon
ECG Low Ejection Fraction Detection and Guiding in AI Navigated Treatment Era Enrolling by invitation
A Multi-center Cardiac PYP Scan Registry in Taiwan Recruiting
iCaReMe Global Registry: Multinational Real-world Evidence in Cardiorenal and Metabolic Diseases Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07862933 on ClinicalTrials.gov ↗ ← All trials in Taiwan